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Abstract
Introduction: HIV self-testing (HIVST) is recommended by the World Health Organization in addition to other testing modali-
ties to increase uptake of HIV testing, particularly among harder-to-reach populations. This study provides the first empirical
evidence of the costs of door-to-door community-based HIVST distribution in Malawi, Zambia and Zimbabwe.
Methods: HIVST kits were distributed door-to-door in 71 sites across Malawi, Zambia and Zimbabwe from June 2016 to May
2017. Programme expenditures, supplemented by on-site observation and monitoring and evaluation data were used to estimate
total economic and unit costs of HIVST distribution, by input and site. Inputs were categorized into start-up, capital and recur-
rent costs. Sensitivity and scenario analyses were performed to assess the impact of key parameters on unit costs.
Results: In total, 152,671, 103,589 and 93,459 HIVST kits were distributed in Malawi, Zambia and Zimbabwe over 12, 11
and 10 months respectively. Across these countries, 43% to 51% of HIVST kits were distributed to men. The average cost per
HIVST kit distributed was US$8.15, US$16.42 and US$13.84 in Malawi, Zambia and Zimbabwe, respectively, with pronounced
intersite variation within countries driven largely by site-level fixed costs. Site-level recurrent costs were 70% to 92% of full
costs and 20% to 62% higher than routine HIV testing services (HTS) costs. Personnel costs contributed from 26% to 52% of
total costs across countries reflecting differences in remuneration approaches and country GDP.
Conclusions: These early door-to-door community HIVST distribution programmes show large potential, both for reaching
untested populations and for substantial economies of scale as HIVST programmes scale-up and mature. From a societal per-
spective, the costs of HIVST appear similar to conventional HTS, with the higher providers’ costs substantially offsetting user
costs. Future approaches to minimizing cost and/or maximize testing coverage could include unpaid door-to-door community-
led distribution to reach end-users and integrating HIVST into routine clinical services via direct or secondary distribution
strategies with lower fixed costs.
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1 | INTRODUCTION
In East and Southern Africa, freely available HIV services have
led to a 42% reduction in AIDS-related deaths between 2010
and 2016. Despite such gains, 24% of people living with HIV
(PLWH) remain undiagnosed [1]. UNAIDS has set global targets
for 90% of PLWH to know their status, 90% of known
HIV-positive individuals, to be on ART and 90% of those on anti-
retroviral therapy (ART) to have their viral load suppressed by
2020 [2]. To surpass and sustain high levels of awareness of HIV
status, greater efforts are needed to ensure that HIV testing
reaches those individuals who have not yet been tested for HIV.
This, however, is likely to require more significant financial invest-
ments, innovative approaches and new technologies, including
HIV self-testing (HIVST).
HIVST is defined as a process where a person collects his/
her own specimen (oral fluid or blood) and then performs an
HIV test and interprets the result, often in a private setting,
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either alone or with someone they trust. The World Health
Organization recommends HIVST to reach the “at risk” and
“untested” populations including men as a complement to cur-
rent conventional testing approaches, including facility-based
and targeted community outreach-based testing [1,3-5]. The
cost of HIVST kits has declined in some settings, with the Ora-
Quick® HIV self-test now costing US$2 per kit in 50 low- and
middle-income countries [6]. However, at US$2, it is around
twice the price of standard HIV rapid diagnostic tests currently
used for HIV testing in Africa [7]. Although HIVST kit price may
be higher, impact analyses show that it can have an important
public health benefit and offer value for money if implemented
as a complement to current testing approaches [4,5].
The HIV Self-Testing AfRica (STAR) project has delivered
over one million HIVST kits in Malawi, Zambia and Zimbabwe
between 2016 and 2017 through a combination of distribution
approaches, including facility-based distribution at outpatient
departments, within voluntary medical male circumcision
(VMMC) services and in the community. This study presents the
costs of the model that uses community-based distribution
agents (CBDAs) to deliver HIVST either at people’s homes or
within the community setting, hereafter “the CBDA model,” to
generate evidence to inform the scale-up of cost-effective HIV
testing services (HTS).
2 | METHODS
2.1 | Setting, intervention and evaluation
Table 1 presents key setting characteristics across countries.
In short, the adult HIV prevalence rates in Malawi, Zambia
and Zimbabwe were approximately 10.0%, 12.0% and 14.6%
respectively [8-10]. While Malawi and Zimbabwe CBDA model
sites were exclusively rural, a third of Zambia sites were peri-
urban or urban. Malawian and Zambian distribution sites were
fewer and each served large populations, while Zimbabwe
delivered kits to a larger number of smaller communities. This
difference in site size is also reflected in the unit costs of con-
ventional facility-based testing, with higher costs in the smaller
facilities in Zimbabwe. It is also notable that men contribute
only 26% to 37% of HTS clients in these facilities.
In the CBDA model, all individuals aged ≥16 years who were
present in the homestead at the time of CBDAs’ home visit
were eligible for self-testing. Testing was done by the self-tester
themselves after kit use demonstration and information on test
result interpretation and linkage to follow-on care by the
CBDAs. CBDAs provided a self-referral card to all testers to
facilitate linkage to the local health facility for confirmatory test-
ing and care for individuals with reactive HIVST results. In some
cases, CBDAs were present during the self-test to provide reas-
surance and support if testers requested their presence or
assistance. Table 2 presents the characteristics of the CBDA
model implemented across countries. Narrative descriptions of
the models can be found in Data S1. The impact of the CBDA
model on uptake of HIV testing and ART is being evaluated in
three cluster-randomized trials (CRTs). Detailed methodology of
these CRTs is published elsewhere [11].
2.2 | Costing methods
We estimated the full economic cost of delivering HIVST
within the CBDA model from the providers perspective, fol-
lowing international costing guidelines [12]. This included
start-up and training costs, prior to the first HIVST kit dis-
tributed. Annual costs were estimated, with implementation
costs collected between June 2016 and May 2017, depending
on country implementation timelines. Start-up, training and all
other capital costs were annualized using a 3% discount rate.
All costs were converted to 2017 US dollars using average
annual exchange rates and the dollar inflation rate [13-15].
This top-down costing collated all financial expenditures and
categorized each line item by input type and distribution
model. Inputs were allocated to distribution sites following
predefined allocation factors, based on project monitoring and
evaluation (M&E) data, including the percentage of kits dis-
tributed, percentage of distributors based in each site, dis-
tance from central office and percentage of direct
expenditures, which is a weighted average of the preceding
Table 1. Key setting characteristics
Malawi Zambia Zimbabwe Source
National HIV prevalence among adults
15 to 59 years (%)
10.0 12.0 14.6 [8–10]
Number of districts 4 4 8 [11]
Number of sites 11 16 44 [11]
Catchment population of sites: mean (range) 27,439
(5500 to 82,581)
18,266
(7673 to 50,094)
3196
(549 to 6699)
[11]
Location: rural (urban or peri-urban) 11 (0) 16 (8) 44 (0) [11]
Scale of current HTS – based on facility
HTS in same communities and period
16,921 27,888 44,727 [16]
Men attendance at HTS – based on facility
HTS – % men
34 37 26 [8–10]
Health facility HTS cost per person tested in
US$: mean (range)
$5.03
($2.96 to $9.24)
$4.24
($2.49 to $6.24)
$8.79
($3.38 to $21.51)
[16]
HTS, HIV testing services.
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allocation factors. Table S1 presents how each allocation fac-
tor was applied to input type. Further detail of the definitions
of project phase and inputs can be found in Data S2.
To estimate economic costs, the expenditure analysis was
complemented by a valuation of all other resources used in
the CBDA model. Observations of distribution in each site
strengthened the economists’ understanding of the interven-
tion and allowed for collection of data on donated goods and
services. As a vertical model, these were relatively limited, and
include a value for district or health facility storage con-
tributed by the public health system. During the life of the
project, the price of HIVST kits dropped from nearly $4 per
kit to $2 per kit. The latter was imputed in place of the higher
observed prices as it was considered the relevant kit price for
any decision-making building upon this analysis. Total costs,
total kits distributed and average cost per kit distributed were
estimated at the country level, and for each country, at the
site level. The latter provides a range of average costs by site
and allows for identification of economies of scale.
2.3 | Sensitivity analysis
We undertook a series of one-way sensitivity analyses to
assess the impact of key cost assumptions on the unit cost
Table 2. Overview of door-to-door community-based HIVST delivery models
Malawi Zambia Zimbabwe
Type of cadre used for
distribution of
HIVST kits
• Trained CBDAs
• Some with prior experience distribut-
ing other reproductive health prod-
ucts for PSI
• Trained facility and CBDAs
• Recruited from communities with
prior links to respective health
facilities
• Trained CBDAs
• Information on HIVST and link-
age to post-test services
Mode of distribution • Door-to-door community-based dis-
tribution
• PSI field teams-maintained stocks
• Door-to-door distribution by
CBDA’s within communities and
households
• Facility-based distributors-main-
tained stocks for CBDAs
• Campaign-style door-to-door
community distribution to
households for four to six
weeks
• PSI field teams-maintained
stocks
Services offered to HIV
self-test clients
• Introduction and demonstration of
HIVST kit use (including interpreta-
tion of results)
• CBDAs typically revisited clients a
few days after dropping off the kit
to:
o enquire whether it had been
used,
o pick up the used kit
o disclosed non-reactive HIVST:
referral to VMMC
o disclosed reactive HIVST: refer-
ral to linkage to HIV care
• Introduction and demonstration of
HIVST kit use (including interpreta-
tion of results)
• CBDAs typically revisited clients a
few days after dropping off the kit
to:
o enquire whether it had been
used
o pick up the used kit
o disclosed non-reactive HIVST:
referral to VMMC
o disclosed reactive HIVST:
referral to linkage to HIV care
• Introduction and demonstration
of HIVST kit use (including
interpretation of results)
• Follow-on services by PSI-Zim-
babwe mobile outreach teams
at one to two weeks post
HIVST kit distribution
o confirmatory HTS plus
o family planning
o blood pressure checks and
CD4 count when available
o clients alerted to linkages
to government health facili-
ties
Used HIVST kit returns • Specially designed and locked drop-
boxes to return used self-test kits
located:
o at all intervention sites
• Specially designed and locked drop-
boxes were used to return used
self-test kits, located:
o at each facility and
o local community public areas
• Specially designed and locked
drop-boxes, located:
o at CBDA’s homestead
o each health facility
o local community public
areas
CBDA reimbursement • Per HIVST kit distributed US$0.15
(MWK 100)
• Monthly US$78 (ZMW 750) inde-
pendent of performance.Later
changed to:
• Per HIVST distributed US$0.52
(ZMW 5) and per used HIVST kit
returned US$0.21 (ZMW 2)
• Per ward campaign (four to
six weeks) US$50 with a maxi-
mum of 100 kits per distributor
• Per HIVST client linking to any
PSI outreach service: $0.20 in
half of the evaluation clusters
HIVST, HIV self-testing; CBDA, community-based distribution agent; PSI, Population Services International; MWK, Malawi Kwacha; ZMW, Zambian
Kwacha.
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per HIVST kit distributed. We varied the discount rate used
to annualize costs from the base case of 3% to 0% and 15%
to capture the impact of not discounting or using a higher
local central bank discount rate. Prevailing discount rates dur-
ing the study period were 15% in Malawi, 12.5% in Zambia
and 7% in Zimbabwe [13-15]. We further evaluated the
impact of applying alternative allocation factors that is swap-
ping % of kits distributed and % of CBDAs per site. We varied
annualization (economic life years) time frames: training & sen-
sitization was varied between one and three years (base case
is two years) and project start-up life between 2.5 and
7.5 years (base case is five years) to assess impact if the pro-
ject goes on for shorter or longer than assumed.
2.4 | Scenario analysis
In anticipation of planned programme scale-up by respective
country ministries of health, we conducted scenario analysis vary-
ing salaries 10% to assess the impact of integration into public
health services, and variation in kit distribution by10%.We also
modelled the impact of HIVST kit price between the observed
average kit price (US$3.40), a recent Bill and Melinda Gates
Foundation subsidized price (US$2) and a hypothetical price
approximately equal to current rapid finger prick test price (US
$1) [16]. Finally, we estimated a best- and worst-case scenario,
the point where all the parameters yield the lowest/highest unit
cost per kit distributed. To generate estimates that are compara-
ble with the costs of ongoing facility HTS in the same communi-
ties in Malawi, Zambia and Zimbabwe [16], we also present costs
without above site-level costs and start-up.
2.5 | Ethics
The study did not involve patient-level data collection; we did,
however, obtain permission from ministries of health in the three
countries to collate data from administrative, M&E records at
facility level for cost allocation. Ethical approvals for the parent
study were obtained from the Medical Research Council of Zim-
babwe, Malawi College of Medicine Research Ethics Committee,
University of Zambia Biomedical Research Ethics Committee,
London School of Hygiene and Tropical Medicine Ethics Commit-
tee and University College London Ethics Committee. The trials
are registered under the Clinical Trials Network (ClinicalTrials.
gov) under registration numbers NCT02793804; NCT02718274;
Pan African clinical trials registry PACTR201607001701788 for
Malawi, Zambia and Zimbabwe.
3 | RESULTS
3.1 | Community-based distribution model
programme outcomes
During the costing period, 152,671, 103,589 and 93,459
HIVST kits were distributed in Malawi, Zambia and Zimbabwe
against the approximate targets of 62,500, 416,294 and
224,116 through a total of 138, 139 and 1009 CBDAs
respectively. The average number of HIVST kits distributed
was 12,538 (range: 4556 to 42,134) across 11 sites in
Malawi, 7206 (range: 1758 to 20,450) across 16 sites in Zam-
bia and 2124 (range: 319 to 4201) across 44 sites in Zim-
babwe, where distribution was intentionally restricted by
campaign duration (Table S2). Nearly half (49%, 51% and
43%, respectively) of the HIVST kits were distributed to men.
3.2 | Total HIVST costs and cost composition
Table 3 summarizes the findings of the cost analysis. The total
distribution costs were calculated as US$1,243,940.66, US
$1,700,730.45 and US$1,293,135.00 in Malawi, Zambia and
Zimbabwe respectively. Capital costs accounted for 3%, 4%
and 2% of the total costs with start-up costs accounting for
15%, 10% and 6% in Malawi, Zambia and Zimbabwe respec-
tively. Within recurrent costs, personnel costs accounted for a
significant portion of total costs, at 26%, 52% and 42% of
costs in Malawi, Zambia and Zimbabwe respectively. Although
the price of kits was centrally negotiated and thus the same
across countries, kits contributed to the largest portion of
total costs in Malawi (34%) and the second largest proportion
in both Zambia and Zimbabwe (14% and 17% respectively).
3.3 | Unit costs
The country-level costs per HIVST kit distributed were US$8.15
for Malawi, US$16.42 for Zambia and US$13.84 in Zimbabwe.
The cost per HIVST kit distributed across the sites ranged from
US$7.20 to US$17.04 in Malawi, US$7.90 to U$50.00 in Zambia
and from US$10.19 to US$54.44 in Zimbabwe. Figure 1 shows
the unit cost per HIVST kit distributed plotted against the scale
of HIVST kits across the three countries. Unit costs were gener-
ally lower at sites that were distributing a larger number of self-
test kits, suggesting a spreading of fixed costs across variable
numbers of kits. When above site-level and start-up costs are
removed our estimates were comparable to the facility HTS unit
costs estimated in the same communities [16]: US$6.67, US
$10.42 and US$10.18 for the CBDA model, compared with facil-
ity HTS unit costs of $5.03 ($2.96 to $9.24), $4.24 ($2.49 to
$6.24) and $8.79 ($3.38 to $21.51) in Malawi, Zambia and Zim-
babwe respectively.
3.4 | Sensitivity and scenario analysis
Figures 2a,b,c show results from the univariate sensitivity and
scenario analyses by country. Our unit costs per HIVST kit dis-
tributed remained robust when key cost parameters were var-
ied. Varying life of start-up training and sensitization between
one and three years resulted in costs of US$7.85 and US
$16.42 versus US$9.07 and US$15.05 in Malawi and Zambia
respectively. For Zimbabwe, however, there was no change to
the base case cost of US$13.84 as training and sensitization
costs were classified as recurrent due to the sequential and
short-term nature of distribution across the eight districts,
requiring training of CBDA who distribute for just four to
six weeks. Varying life of start-up life or development phase
between 2.5 and 7.5 years resulted in costs of US$8.23, US
$15.40 and US$14.42 compared to US$8.13, US$14.28 and US
$13.63 in Malawi, Zambia and Zimbabwe respectively.
Varying HIVST kit price between US$1 and US$3.40
yielded costs of US$6.44, US$15.15 and US$12.25 versus US
$8.87, US$17.60 and US$14.99 in Malawi, Zambia and Zim-
babwe respectively. Varying salaries by 10% yielded costs of
US$7.94, US$15.57 and US$13.24 versus US$8.37, US$17.27
and US$14.43 respectively. Varying kit quantity by 10%
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yielded costs of US$7.41, US$15.63 and US$12.83 versus US
$9.06, US$17.60 and US$15.07 respectively. The best-case
scenario was US$6.14, US$13.99 and US$12.32 per kit dis-
tributed, whereas the worst-case scenario was US$10.27, US
$20.12 and US$21.85 per kit distributed.
4 | DISCUSSION
This is the first published study to present costs of door-to-
door CBDA delivery of HIVST kits in Malawi, Zambia and
Zimbabwe. Costs ranged from as low as US$7.20 at a very
large distribution site where CBDA distribution of HIVST kits
was integrated with the delivery of other health products, to
US$54.55 with campaign-style delivery in a very small com-
munity in Zimbabwe that would otherwise not have access to
testing. Staff costs contributed a substantial portion of the
costs highlighting potential opportunities for lower cost mod-
els from reconfiguring distribution to rely on unpaid volun-
teers within door-to-door community-led distribution models.
Additionally, economies of scale can clearly be optimized. In
this analysis, we showed how unit costs fall as the number of
Table 3. HIV self-test kit distribution cost breakdown and key cost contributors (in 2017 US$)
Input type
Malawi
Kits distributed: 152,671
12 months: June 2016
to May 2017
Zambia
Kits distributed: 103,589
11 months: July 2016
to May 2017
Zimbabwe
kits distributed: 93,459
10 months: August 2016
to May 2017
Intervention cost % Intervention cost % Intervention cost %
Start-up
Training $11,313.34 1% $31,000.73 2% $3,149.10 0%
Sensitization $58,485.72 5% $58,306.80 3% $2,694.30 0%
Start-up other $108,409.87 9% $84,745.15 5% $75,942.83 6%
Capital costs
Building and storage
Central $16,755.33 1% $54,077.43 3% $3,266.62 0%
Warehouse $– – $– – $– –
Site level $– – $– – $– –
Equipment
Central equipment $28,026.91 2% $13,597.20 1% $14,759.28 1%
Site level $– – $– – $7,621.29 1%
Vehicles and bicycles $3,162.38 0% $– – $– –
Other capital $– – $– – $35.14 0%
Total costs (capital and start-up) $226,153 18% $241,727 14% $107,468 8%
Recurrent costs
Personnel $318,129.23 26% $880,688.56 52% $555,187.86 42%
HIV self-test kits $418,584.61 34% $237,303.53 14% $219,627.52 17%
Supplies
T-shirts, bags, flipcharts $35,611.73 3% $78,569.63 5% $67,757.98 5%
Other supplies $– – $– – $142,543.96 11%
Vehicle operation, maintenance
and transport
$109,240.41 9% $148,117.37 9% $57,396.14 4%
Building operation/maintenance
Central $2,204.87 0% $19,416.76 1% $18,602.17 1%
Warehouse $– – $– – $13,141.39 1%
Site level $– – $– – $– –
Recurrent training $13,409.18 1% $19,235.49 1% $90,440.92 7%
Waste management $– – $– – $554.89 0%
Other recurrent $120,607.08 10% $75,671.83 4% $20,414.02 2%
Total costs (recurrent) $1,017,787 82% $1,459,003 86% $1,185,667 92%
Total CBDA HIVST costs $1,243,940 100% $1,700,730 100% $1,293,135 100%
Cost per kit distributed $8.15 $16.42 $13.84
Note that totals have been rounded to the nearest US$.
HIVST, HIV self-testing; CBDA, community-based distribution agent.
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kits distributed increases. As all modes of testing are scaled
up and testing coverage increases, it will be critical to target
populations efficiently, with special focus on communities
underserved by facility-based HTS.
Although costs are presented from a provider’s perspective,
door-to-door community HIVST distribution relieves users
from substantial direct and indirect costs of attending health
facilities. A study in these same communities in Malawi
showed the mean costs of accessing HIV testing among
women and men as US$1.83 and US$3.81, respectively, with
men reporting significantly higher opportunity costs (i.e. lost
income) [17]. Community HIVST distribution reduces these
costs to nearly zero, as kits are delivered in the home with no
waiting times. We can, therefore, estimate the societal costs
of facility-based HIV testing in Malawi as US$6.86 for women
and US$8.84 for men (the user costs reported above and the
provider costs as reported by Mwenge et al. [16]). This is
comparable with our observed HIVST societal costs (excluding
start-up and above service level costs: US$6.67) in Malawi.
Thus, HIVST may provide for unmet testing needs among
Figure 1. HIV self-testing (HIVST) costs per HIVST kit distributed by site and quantity in 2017 US$.
Figure 2. (a, b, c) Tornado diagrams of findings from deterministic sensitivity analysis (univariate and scenario analyses) in Malawi, Zambia
and Zimbabwe.
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remotely or never-tested individuals, or others with high user
costs of accessing facility-based testing.
HIVST costs reflected across all three countries are not dis-
similar to those reported previously in Malawi ($8.78 in 2016
US$) [18]. We also found the cost of door-to-door community
HIVST distribution to be comparable to standard community-
based HIV testing in sub-Saharan Africa (range: US$7.37 to US
$36.93) [19,20]. While we did find that CBDA delivered HIVST
under this early demonstration and research programmes were
more costly than facility-based HIV testing [16,18], we also
found HIVST reached many more individuals. During the period
of this costing study, health facilities serving the study commu-
nities provided HIV testing to approximately 17,000, 28,000
and 45,000 people, while the HIVST service distributed approxi-
mately 152,671, 104,000 and 94,000 kits in Malawi, Zambia
and Zimbabwe respectively. Importantly, half of the HIVST kits
were distributed to men, while only 26% to 37% of facility HIV
testing clients were men [8-10], the population group primarily
contributing to the HIV testing gap.
We anticipate potential for substantial economies of scale
as HIVST programmes scale-up and mature. The door-to-door
community HIVST distribution model costed for this current
study was implemented by a non-governmental organization,
under a research protocol, using paid and incentivized CBDAs
and delivered to predominantly rural communities with no
previous knowledge of, or experience with, HIVST. Interven-
tions delivered in a research context tend to be associated
with higher costs, as the primary objective is achieving effec-
tiveness. Large-scale implementation through door-to-door
community-led HIVST distribution with ordinarily paid govern-
ment providers or community residents is likely to be signifi-
cantly less costly. There are additional potential costs savings.
First, we found costs were lower in high kit distribution sites
suggesting economies of scale and ability to deliver at lower
costs in more densely populated communities. Second, 10% to
20% of the costs were start-up and initial capital costs, which
would decrease as services mature. Third, as general popula-
tions and providers gain a better understanding of HIVST as a
screening technology, we would expect less intense need for
CBDAs (and therefore, less intense need for training work-
shops) and community sensitization activities.
Additionally, CBDAs could incorporate HIVST delivery into
other health service activities thereby delivering cost savings to
providers through economies of scope in services delivered by
the CBDAs. Finally, as the HIVST market grows, technology
advances and newer manufacturers enter, the price of HIVST kits
will likely fall to prices comparable to blood-based kits currently
used in health facilities and in-person support requirements
could, in theory, could become cheaper than provider-supervised
testing. In this case, HIVST could save costs and allow providers
to focus on confirmatory testing and strengthening linkage to
ART [21,22]. To identify this, it will be important to take a full sys-
tem costing approach. Such data have been collated and will be
analysed jointly to inform cost-effectiveness modelling.
From a research perspective, the wide cost variations high-
light the importance of evaluating costs across a variety of
settings in order to generate means and confidence intervals.
Future analyses of these data may generate useful insights
into efficiency and provide key inputs into modelled cost-
effectiveness analyses. It would also be important to expand
conventional sensitivity analyses to assess unit costs when
these observed ranges are included or when unit costs are
incorporated as a function of scale. Furthermore, considering
that our analysis only shows the costs of implementing CBDA
model for a non-governmental perspective and that these
costs can vary if the kits were distributed differently, an
important next research question will be to explore the costs
of possible HIVST distribution modalities such as secondary
distribution and social marketing models among others.
4.1 | Limitations
The findings of our cost analyses are limited to unit costs per
kit distributed as the private nature of the HIVST did not
allow us to estimate the costs of identifying new HIV-positive
individuals or those HIV-positive individuals linked to treat-
ment through HIVST. In addition, our results are borne out of
a research trial setting and may not truly reflect a real-world
situation: for example, site fixed transport costs are likely
higher due to the distances between the trial communities,
while in routine scale-up, all communities would receive HIVST
kits and transport would be shared across far higher scale.
Additionally, as HIVST was a new product, distribution was
conservative, restricting the numbers of kits that each CBDA
could distribute in Zimbabwe, and so constraining opportuni-
ties to operate at larger scale. Consequently, costs were likely
higher than future routine implementation. The benefits of
HIVST distribution may also be restricted by test performance
characteristics such as sensitivity, specificity and ability of the
user to read the test as well as rates of linkage to care. An
important consideration would be the optimal, setting-specific
incentive structure for door-to-door community-based distri-
bution of the kits. It is important to highlight that for purposes
of this analyses authors had not collated and analysed data on
self-test kit utilization. However, previous work has not only
shown high uptake of HIVST but also high levels of kit utiliza-
tion by recipients [4]. Key strengths of this cost analysis are
the estimation of costs across seventy-one sites in three
Southern African countries. The costing teams used standard-
ized costing guidelines and collaboratively analysed data
ensuring consistency of methods across countries and applica-
tion of a range of sensitivity and scenario analyses exploring
the impact of our assumptions.
4.2 | Implications
Countries keen to achieve impact and meet the global testing
and treatment targets will likely need to invest in a mixture of
HIV testing approaches, including door-to-door community
delivered HIVST targeted at populations with financial or
other barriers to obtaining HIV testing in health services, that
is people living in settings with high undiagnosed HIV or
remote communities, and groups such as men and adoles-
cents. Reducing costs during short-term scale-up and imple-
mentation of this model should focus on economies of scope
and scale and ensure efficiencies in personnel and transporta-
tion costs. Alternative cost-minimization approaches also need
to be explored for acceptability, impact and affordability, aim-
ing to provide affordable access to HIVST nationally, for exam-
ple integrating HIVST within the existing facility and
community health services, secondary distribution from facili-
ties including partner delivered and peer-network approaches.
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5 | CONCLUSIONS
Staff costs were a substantial cost contributor highlighting the
potential for lower cost models if distribution relied on unpaid vol-
unteers within door-to-door community-led distribution models.
Economies of scale can also be optimized with our costs
showing reductions when kits are distributed in higher num-
bers. Across all three countries, our HIVST cost estimates
were not dissimilar to previous door-to-door community-based
HIVST and standard community-based HIV testing models
costed in sub-Saharan Africa. Although the costs of CBDA
delivered HIVST were higher than facility-based HIV testing
the evidence shows HIVST reaches many more individuals. A
significant portion (almost half) of HIVST kits were distributed
to men (key contributors to the HIV testing gap) compared to
only 26% to 37% for facility HIV testing.
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